National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Despite ineffective treatments, chemotherapy is common for diffuse midline gliomas (DMG). Comorbidity index and race significantly impact survival in these aggressive brain tumors.
Area Of Science
- Neuro-oncology
- Cancer genomics
- Clinical research
Background
- Diffuse midline gliomas (DMG) are aggressive World Health Organization grade 4 brain tumors.
- Characterized by histone H3 K27M mutation, DMG has a poor prognosis with mean survival of 9-19 months.
- No standard treatment exists, with radiation offering only marginal survival benefits.
Purpose Of The Study
- To analyze current treatment trends for diffuse midline gliomas (DMG).
- To identify predictors of overall survival in adult patients with DMG.
- To evaluate the impact of various factors on DMG patient outcomes.
Main Methods
- Retrospective analysis of the National Cancer Database (2016-2020).
- Included adult patients treated with primary brain radiation, with or without chemotherapy.
- Univariable and multivariable Cox regression models were employed to identify survival predictors.
Main Results
- 131 patients met inclusion criteria; 86% received concurrent chemotherapy with radiation.
- Charlson-Deyo comorbidity index and race were significant predictors of survival.
- Higher comorbidity scores and non-White/Black race were associated with increased mortality risk.
Conclusions
- Chemotherapy is frequently administered to DMG patients despite questionable efficacy.
- Charlson-Deyo comorbidity index and patient race are critical prognostic factors for DMG survival.
- Further research is needed to establish effective treatment standards for DMG.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.